International Congress on Neuromuscular Diseases (ICNMD), 2024

Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalised myasthenia gravis (MG0004)

Bril Vera, Grosskreutz Julian, Habib A. Ali, et al.

Oral Presentation

Ocular symptoms in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG

Habib A. Ali, Pascuzzi M. Robert, Vissing John, et al.

Oral Presentation

Response rates with zilucoplan in generalised myasthenia gravis: 120-week interim analysis of RAISE-XT

James F. Howard Jr., Freimer Miriam, Genge Angela, et al.

Oral Presentation

Switching to subcutaneous zilucoplan from IV C5 inhibitors in myasthenia gravis: A Phase 3b study

James F. Howard Jr., Desai Urvi, Govindarajan Raghav, et al.

Poster

Corticosteroid dose tapering with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT

M. Isabel Leite, Freimer Miriam, Genge Angela, et al.

Poster